Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest Update

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) was the recipient of a significant decrease in short interest during the month of December. As of December 31st, there was short interest totalling 22,600 shares, a decrease of 60.8% from the December 15th total of 57,600 shares. Based on an average daily trading volume, of 175,600 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.4% of the company’s stock are sold short.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Rodman & Renshaw assumed coverage on Adial Pharmaceuticals in a research report on Thursday, November 14th. They issued a “buy” rating and a $8.00 price target for the company. RODMAN&RENSHAW raised Adial Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, November 14th.

Adial Pharmaceuticals Stock Performance

Shares of Adial Pharmaceuticals stock opened at $1.02 on Thursday. The firm has a fifty day simple moving average of $1.06 and a 200-day simple moving average of $1.04. Adial Pharmaceuticals has a 1-year low of $0.77 and a 1-year high of $4.17.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.